Kardigan (KARD) logo

Kardigan's IPO

Kardigan · Filed May 26 · Nasdaq · Form S-1

Listed Jun 18, 2026 at $16 on Nasdaq as KARD. Today 28% below its $16 offer price; its first day closed +37.5%.

Offer price: $16, a share
Market cap: $1.43B, from its filing
Shares: 25M, offered

From its final prospectus (424B4) on SEC EDGAR.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

See KARD ranked, liveSee KARD ranked, liveSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What does Kardigan do?

Kardigan's facts, each with its source
FactKardigan
What it does“Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist.”From its final prospectus (424B4) of Jun 18, 2026
Founded2023From its final prospectus (424B4) of Jun 18, 2026
IncorporatedDelaware, 2023From its final prospectus (424B4) of Jun 18, 2026
HeadquartersPrinceton, New JerseyFrom its final prospectus (424B4) of Jun 18, 2026
Employees241 full-time, as of March 31, 2026From its final prospectus (424B4) of Jun 18, 2026
Websitekardigan.bioFrom its final prospectus (424B4) of Jun 18, 2026

What is the offering?

Each figure names the filing it is from and that filing's date. The market cap is Breakaway's arithmetic from the prospectus's share count.

Kardigan's facts, each with its source
FactKardigan
Shares offered25,000,000From the final prospectus (424B4) filed Jun 18, 2026
Offer price$16 a shareFrom the final prospectus (424B4) filed Jun 18, 2026
Raised at that price$400 millionFrom the final prospectus (424B4) filed Jun 18, 2026
Underwriters' discount$28 millionFrom the final prospectus (424B4) filed Jun 18, 2026
Net proceeds the company expectsAbout $367 millionFrom the final prospectus (424B4) filed Jun 18, 2026
Underwriters' option3,750,000 more sharesFrom the final prospectus (424B4) filed Jun 18, 2026
UnderwritersJ.P. Morgan, Jefferies, Leerink Partners, and TD CowenFrom the final prospectus (424B4) filed Jun 18, 2026, as its cover names them
ExchangeNasdaq Global Market, as KARDFrom the final prospectus (424B4) filed Jun 18, 2026
Shares outstanding after89,339,121From the final prospectus (424B4) filed Jun 18, 2026
Market cap at the offer price$1.43 billionBreakaway's arithmetic from the prospectus's share count

What the filing says about its money

Kardigan's facts, each with its source
FactKardigan
RevenueNone from product sales yetFrom its final prospectus (424B4) of Jun 18, 2026: it has not generated any revenue from product sales or other sources
Last preferred stockSeries B preferredFrom its final prospectus (424B4) of Jun 18, 2026
Raised before the IPO$568 million in private financingsFrom its final prospectus (424B4) of Jun 18, 2026

What risks does Kardigan name first?

  1. “We are a clinical-stage biopharmaceutical company with a limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability.”
  2. “Even if this offering is successful, we will require additional funding in order to finance our operations.”
  3. “Our business is highly dependent on the success of our product candidates, particularly Danicamtiv for genetic DCM, Ataciguat for moderate CAVS, and Tonlamarsen for post-hospitalization management of ASH. If we are unable to successfully complete clinical development…”

The first three of the risks its prospectus summary lists, in the company's words. The rest, and each in full, are in the filing. Read the filing.

Dates so far

Kardigan's IPO dates, each with its source
WhatDay
Registration filedForm S-1, SEC EDGARMay 26, 2026
Exchange registration filedexchange registration (Form 8-A), SEC EDGARJun 15, 2026
Declared effective by the SECSEC notice of effectiveness, SEC EDGARJun 17, 2026
Pricedfinal prospectus (424B4), filed Jun 18, SEC EDGARJun 17, 2026
First tradeMassive's IPO calendarJun 18, 2026
Lock-up endsfinal prospectus, SEC EDGAR: “180 days after the date of this prospectus”Dec 14, 2026

How did its first days trade?

From its daily bars, each close against its $16 offer price.

Kardigan's first sessions
DayOpenCloseFrom the
offer
Jun 18$16.25$22+37.5%
Jun 22$21.29$22.77+42.3%
Jun 23$22.96$22.24+39.0%
Jun 24$21.68$22.03+37.7%
Jun 25$22.28$22.58+41.1%

What is Kardigan's Quality Score?

0

Poor

109 trading days so far; 3 of the 14 checks wait for more history.

KARD's page, with every reason behind its score

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

The other IPOs expected

The other IPOs expected or in registration
CompanyPrice

Kardigan IPO questions

When is Kardigan's IPO?

Listed Jun 18, 2026 at $16 on Nasdaq as KARD.

What is Kardigan's IPO price?

Kardigan's IPO priced at $16 a share, per its final prospectus of Jun 18, 2026.

How many shares is Kardigan selling?

25,000,000 shares, and the underwriters may buy 3,750,000 more, per its final prospectus (424B4).

Who are the underwriters?

J.P. Morgan, Jefferies, Leerink Partners, and TD Cowen, as the prospectus's cover names them.

When does the lock-up end?

Kardigan's IPO lock-⁠up ends Dec 14, 2026. Its final prospectus says: “180 days after the date of this prospectus.”

Does Breakaway rate Kardigan?

Kardigan has a Quality Score of -2 today. The score counts the 14 chart checks and the company's filings; a check that needs more history than a new stock has waits for it.

Can Breakaway say where Kardigan's price will go?

No. Breakaway does not say where a price will go. Every figure here is from the company's SEC filings, linked on each line.

Where every figure comes from: how the IPO pages are made.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Every new listing, ranked live.

Each stock that listed in the last 90 days, with its Quality Score from its second day of trading, its insider filings, and its lock-up date, and an optional alert the day a company you follow lists.

See all 12 new listings rankedSee all 12 new listings rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Sources: Kardigan, Inc.'s final prospectus (424B4) of Jun 18, 2026; the prices, the stock's daily bars, 15 minutes behind.

Not advice. Figures from each company's SEC filings, linked on each line. Breakaway is not an underwriter, broker, or adviser, and does not say where a price will go.

Scores as of 8:50 PM ET, 15 minutes behind.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.